What is the history of Minimal change disease?

Minimal change disease was first clinically characterized in the early 20th century, though it remained poorly understood until the advent of electron microscopy in the 1950s. This diagnostic breakthrough revealed that the condition is defined by the "minimal" structural changes visible under light microscopy, fundamentally shifting our understanding from a vague kidney ailment to a specific podocytopathy.

When was Minimal change disease first described?

While physicians had long observed patients with nephrotic syndrome—characterized by significant protein loss in the urine—the specific pathology of Minimal change disease remained elusive for decades. In the early 1900s, it was often grouped under the broad, imprecise label of "lipoid nephrosis" because early pathologists observed lipid-filled cells in the kidney tubules. It was not until the 1950s that researchers, most notably Dr. Jacob Churg and Dr. Elaine Feldman, utilized the newly developed electron microscope to examine kidney biopsies. They discovered that the hallmark of Minimal change disease was not the lipid deposits themselves, but the effacement (flattening) of the podocyte foot processes, a structural detail invisible to standard light microscopes.

How has our understanding of Minimal change disease evolved?

The evolution of our knowledge regarding Minimal change disease has been a transition from descriptive pathology to molecular biology. Initially, the disease was considered a primary disorder of the kidney tubules. Today, we classify it as a podocytopathy—a disease of the specialized cells that form the filtration barrier of the glomerulus. We now understand that Minimal change disease is likely triggered by a circulating factor, possibly related to T-cell dysfunction, which causes the podocytes to retract and lose their ability to prevent protein leakage.

What were the major milestones in treatment?

The history of treating Minimal change disease is marked by the transition from supportive care to targeted immune modulation. Before the mid-20th century, prognosis was often poor, with patients relying on diuretics and low-salt diets. The major milestones include:

• 1950s: The introduction of corticosteroids, which remains the first-line therapy today, revolutionized the outlook for patients.


• 1970s-80s: The use of alkylating agents like cyclophosphamide was introduced for patients who were steroid-dependent or resistant.


• Modern Era: The development of calcineurin inhibitors (like cyclosporine and tacrolimus) and B-cell depleting therapies (like rituximab) has provided new options for managing relapses.

How have modern genetics and technology changed the landscape?

While Minimal change disease is primarily considered an acquired (idiopathic) condition, genetic research has provided critical insights. We now know that some cases previously labeled as Minimal change disease are actually hereditary forms of nephrotic syndrome caused by mutations in genes like NPHS1 or NPHS2. This realization has allowed clinicians to use genetic testing to distinguish between autoimmune-driven disease and genetic podocyte defects, which do not respond to immunosuppression. Today, the 68 members of the DiseaseMaps.org community contribute to a collective understanding that helps bridge the gap between historical clinical observations and modern patient-centered care.

Next steps

• Consult a board-certified nephrologist to discuss whether a kidney biopsy or genetic testing is appropriate for your specific clinical presentation.


• Monitor your proteinuria levels consistently, as tracking these numbers is the historical gold standard for gauging treatment response.


• Join the DiseaseMaps.org community to connect with others who have navigated the history and management of this condition.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Minimal change disease overview.


• Orphanet: Minimal change nephrotic syndrome (ORPHA:654).


• OMIM (Online Mendelian Inheritance in Man): Nephrotic syndrome, idiopathic, with minimal change disease.


• National Kidney Foundation: History and clinical management of nephrotic syndrome.